Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells

International Journal of Cancer

Volumn 136, Issue 11, 2015, Pages 2566-2578

  Authier, Astrid ^a   Farrand, Kathryn J ^a   Broadley, Kate W R ^a   Ancelet, Lindsay R ^a   Hunn, Martin K ^a,b   Stone, Sarrabeth ^b   McConnell, Melanie J ^b   Hermans, Ian F ^a,b  

^a MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

^b VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

chemotherapy; glioblastoma multiforme; glioma; immunosuppression; immunotherapy; prostaglandin E2; radiotherapy

Indexed keywords

DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 6; PROSTAGLANDIN E2; TEMOZOLOMIDE; CULTURE MEDIUM; CYTOKINE;

ACCESSORY CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INTERACTION; CONTROLLED STUDY; CULTURE MEDIUM; GAMMA IRRADIATION; GLIOBLASTOMA CELL LINE; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; UPREGULATION; ANIMAL; BRAIN NEOPLASMS; C57BL MOUSE; CANCER TRANSPLANTATION; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GLIOBLASTOMA; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHARMACOLOGY; RADIATION RESPONSE; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMMUNOSUPPRESSION; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION;

EID: 84924891854     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29309     Document Type: Article

References (42)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
2. Reardon DA, Herndon JE, II, Peters K, et al. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. J Neuro-oncol 2012; 107: 213-21.
3. Chen C, Xu T, Lu Y, Chen J, Wu S,. The efficacy of temozolomide for recurrent glioblastoma multiforme. Eur J Neurol 2013; 20: 223-30.
4. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-60.
5. Liu Q, Nguyen DH, Dong Q, et al. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neuro-oncol 2009; 94: 1-19.
6. Steiner HH, Bonsanto MM, Beckhove P, et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol 2004; 22: 4272-81.
7. Ardon H, Van Gool S, Lopes IS, et al. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neuro-oncol 2010; 99: 261-72.
8. Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 2013; 62: 125-35.
9. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346-57.
10. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
11. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-65.
12. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22.
13. Waziri A,. Glioblastoma-derived mechanisms of systemic immunosuppression. Neurosurgery clinics of North America 2010; 21: 31-42.
14. Jackson C, Ruzevick J, Phallen J, et al. Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin Dev Immunol 2011; 2011: 732413.
15. Fadul CE, Fisher JL, Gui J, Hampton TH, Cote AL, Ernstoff MS,. Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro-oncology 2011; 13: 393-400.
16. Newcomb EW, Zagzag D,. The murine GL261 glioma experimental model to assess novel brain tumor treatments. CNS Cancer Cancer Drug Discov Dev 2009: 227-241.
17. Broadley KW, Hunn MK, Farrand KJ, et al. Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme. Stem Cells 2011; 29: 452-61.
18. Chen J, Li Y, Yu TS, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012; 488: 522-6.
19. Lindau D, Gielen P, Kroesen M, et al. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 2013; 138: 105-15.
20. Lindqvist CA, Christiansson LH, Simonsson B, et al. T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies. Immunology 2010; 131: 371-6.
21. Kvirkvelia N, Vojnovic I, Warner TD, et al. Placentally derived prostaglandin E2 acts via the EP4 receptor to inhibit IL-2-dependent proliferation of CTLL-2 T cells. Clin Exp Immunol 2002; 127: 263-9.
22. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006; 66: 3294-302.
23. Morford LA, Elliott LH, Carlson SL, et al. T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol 1997; 159: 4415-25.
24. Ogden AT, Horgan D, Waziri A, et al. Defective receptor expression and dendritic cell differentiation of monocytes in glioblastomas. Neurosurgery 2006; 59: 902-9; discussion 09-10.
25. Zou JP, Morford LA, Chougnet C, et al. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J Immunol 1999; 162: 4882-92.
26. Crane CA, Ahn BJ, Han SJ, Parsa AT,. Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro-oncology 2012; 14: 584-95.
27. Wei J, Barr J, Kong LY, et al. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther 2010; 9: 67-78.
28. Obermajer N, Wong JL, Edwards RP, et al. PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells. Immunol Invest 2012; 41: 635-57.
29. Rincon M, Tugores A, Lopez-Rivas A, et al. Prostaglandin E2 and the increase of intracellular cAMP inhibit the expression of interleukin 2 receptors in human T cells. Eur J Immunol 1988; 18: 1791-6.
30. Baratelli F, Lin Y, Zhu L, et al. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 2005; 175: 1483-90.
31. von Bergwelt-Baildon MS, Popov A, Saric T, et al. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 2006; 108: 228-37.
32. Sawamura Y, Diserens AC, de Tribolet N,. In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes. J Neuro-oncol 1990; 9: 125-30.
33. Kuppner MC, Sawamura Y, Hamou MF, de Tribolet N,. Influence of PGE2- and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2-activated lymphocytes. J Neurosurg 1990; 72: 619-25.
34. Williams CS, Mann M, DuBois RN,. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18: 7908-16.
35. Karim A, McCarthy K, Jawahar A, et al. Differential cyclooxygenase-2 enzyme expression in radiosensitive versus radioresistant glioblastoma multiforme cell lines. Anticancer Res 2005; 25: 675-9.
36. Bijnsdorp IV, van den Berg J, Kuipers GK, et al. Radiosensitizing potential of the selective cyclooygenase-2 (COX-2) inhibitor meloxicam on human glioma cells. J Neuro-oncol 2007; 85: 25-31.
37. Tuettenberg J, Grobholz R, Seiz M, et al. Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy. J Cancer Res Clin Oncol 2009; 135: 1239-44.
38. Tuettenberg J, Grobholz R, Korn T, et al. Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 2005; 131: 31-40.
39. Stockhammer F, Misch M, Koch A, et al. Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma. J Neuro-oncol 2010; 100: 407-15.
40. Eberstal S, Badn W, Fritzell S, et al. Inhibition of cyclooxygenase-2 enhances immunotherapy against experimental brain tumors. Cancer Immunol Immunother 2012; 61: 1191-9.
41. Toomey D, Conroy H, Jarnicki AG, et al. Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma. Vaccine 2008; 26: 3540-9.
42. Hahn T, Alvarez I, Kobie JJ, et al. Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer. Int J Cancer 2006; 118: 2220-31.